Rybelsus (semaglutide (oral)) has 0 documented side effects from peer-reviewed Phase 3 trial data. Click any effect for a patient-facing deep dive with management guidance.
Side-effect incidence data for Rybelsus is being added. In the meantime, see general GLP-1 side effects at /glp1-side-effects.
Incidence rates from peer-reviewed pivotal-trial publications and FDA prescribing information. Individual experience varies — discuss any new symptoms with your prescriber. Medically reviewed by Jane Novak, MD, MPH.